# A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

> **NCT07123441** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sanjun Cai** · enrollment: 300 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab,Irinotecan liposome (II),5-FU/LV

## Key facts

- **NCT ID:** NCT07123441
- **Lead sponsor:** Sanjun Cai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123441, "A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07123441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*